Rusfertide Demonstrates Durable Response in Polycythemia Vera Patients

Protagonist Therapeutics and Takeda presented new data at ASH 2025, showing that rusfertide delivered durable response and hematocrit control in polycythemia vera patients. The 52-week results from the pivotal Phase 3 VERIFY study demonstrated that 61.9% of patients continuously treated with rusfertide maintained absence of phlebotomy eligibility from baseline to Week 52. The findings reinforce rusfertide's efficacy and safety, and its potential as a new addition to the standard of care for PV patients.